Cardiovascular Risk And Prevention - USMLE Step 2

1. A 28-year-old woman presents for a pre-employment physical. She has obesity (BMI 34 kg/m²) and smokes 8 cigarettes/day. She reports high job stress and sleeps 5 hours/night. BP is 142/90 mm Hg (repeat 140/88). Labs: total cholesterol 182 mg/dL, LDL 110 mg/dL, HDL 39 mg/dL, triglycerides 170 mg/dL, fasting glucose 99 mg/dL. She takes no medications. Family history: father had hypertension; no early CAD. She asks which recommendation would most reduce her cardiovascular risk. What preventive measure should be prioritized for this patient?
   Answer: Recommend smoking cessation with pharmacotherapy options This question tests cardiovascular risk and prevention for USMLE Step 2 CK, specifically understanding risk reduction in young adults. Cardiovascular risk management involves assessing smoking, obesity, and hypertension, with preventive strategies prioritizing cessation. In the vignette, the patient's smoking, obesity, stress, and BP elevate long-term risk. The correct answer, 'Recommend smoking cessation with pharmacotherapy options,' aligns with guidelines for comprehensive support to quit. Choice A, starting aspirin, is not indicated for primary prevention here. To help students: Discuss cessation pharmacotherapy, assess readiness to quit, and calculate lifetime vs. 10-year risk.
2. A 27-year-old man with obesity (BMI 33 kg/m²) and smoking presents for BP recheck. He smokes 15 cigarettes/day and reports high stress and minimal exercise. BP is 150/94 mm Hg. Labs: LDL 118 mg/dL, HDL 37 mg/dL, triglycerides 200 mg/dL, fasting glucose 102 mg/dL. He is not on medications. Family history is negative for early CAD. He asks whether vaping or "cutting down" is enough. What preventive measure should be prioritized for this patient?
   Answer: Recommend complete smoking cessation with counseling This question tests cardiovascular risk and prevention for USMLE Step 2 CK, specifically understanding smoking cessation in young adults. Cardiovascular risk management involves addressing smoking as a top priority. In the vignette, the patient's smoking, obesity, hypertension, and lipids highlight cessation needs. The correct answer, 'Recommend complete smoking cessation with counseling,' aligns with guidelines over alternatives like vaping. Choice A, switching to vaping, is not safer long-term. To help students: Discuss cessation resources, assess dependence, and debunk reduced-harm myths.
3. Which of the following is the most appropriate next step in managing this patient's hyperlipidemia?
   Answer: Add ezetimibe This patient has established atherosclerotic cardiovascular disease (secondary prevention) and is considered very high risk. For very high-risk patients on maximally tolerated statin therapy, the goal is to achieve an LDL cholesterol level of <70 mg/dL (or even <55 mg/dL per some guidelines). Since his LDL is 85 mg/dL on a high-intensity statin, the next step is to add a non-statin agent. Ezetimibe is the first-line add-on therapy in this situation. A PCSK9 inhibitor would be considered if the LDL remains elevated after adding ezetimibe.
4. Which of the following is the most appropriate action to further refine her lifetime cardiovascular risk?
   Answer: Measure lipoprotein(a) This patient has a very strong family history of premature atherosclerotic cardiovascular disease, which is a major risk-enhancing factor not fully captured by the 10-year ASCVD risk score. Lipoprotein(a) is a highly atherogenic, genetically determined lipoprotein. Elevated levels are an independent risk factor for ASCVD, particularly in individuals with a strong family history. Measuring Lp(a) can help reclassify her risk and inform decisions about more aggressive preventive strategies. hs-CRP is another risk enhancer, but Lp(a) is more specific in the context of a strong genetic predisposition.
5. A 61-year-old postmenopausal woman with type 2 diabetes presents for follow-up. She is adherent to metformin; A1c is 6.6%. She is sedentary and has BMI 29 kg/m². BP is 130/78 mm Hg. Lipids: LDL 116 mg/dL, HDL 45 mg/dL, triglycerides 165 mg/dL. She is not on lipid-lowering therapy. Family history includes mother with MI at 55. She asks which medication adjustment most reduces cardiovascular risk. Which medication adjustment is most indicated based on the patient's profile?
   Answer: Start moderate- to high-intensity statin therapy This question tests cardiovascular risk and prevention for USMLE Step 2 CK, specifically understanding lipid management in diabetic patients with additional risk factors. Cardiovascular risk management involves evaluating ASCVD risk in diabetics, where guidelines recommend statin therapy for those aged 40-75 to reduce events, alongside lifestyle modifications. In the vignette, the patient's type 2 diabetes, postmenopausal status, family history of early MI, sedentary lifestyle, and elevated LDL indicate a high risk, warranting pharmacologic intervention despite controlled A1c and blood pressure. The correct answer, 'Start moderate- to high-intensity statin therapy,' is most indicated as it directly targets LDL reduction and is first-line for cardiovascular risk reduction in this profile per ACC/AHA guidelines. Choice B, starting fenofibrate, is incorrect because it is not primary for LDL management and is typically used for severe hypertriglyceridemia. To help students: Focus on memorizing statin indications in diabetes, including risk enhancers like family history, and avoid common pitfalls such as prioritizing therapies like niacin that have limited evidence. Practice integrating patient profiles with guidelines to select evidence-based adjustments over unnecessary changes like stopping effective medications.
6. According to current guidelines, which of the following is the most appropriate management for his dyslipidemia?
   Answer: Initiate moderate-intensity statin therapy Guidelines recommend that all patients with diabetes mellitus aged 40 to 75 years should be treated with at least a moderate-intensity statin, regardless of their baseline LDL cholesterol or calculated 10-year ASCVD risk. High-intensity statin therapy is recommended for diabetic patients with a higher ASCVD risk (≥20%) or multiple ASCVD risk factors. Since this patient's risk is 8%, a moderate-intensity statin (e.g., atorvastatin 10-20 mg, rosuvastatin 5-10 mg) is the most appropriate initial choice.
7. Which of the following is the most appropriate intervention for primary prevention of atherosclerotic cardiovascular disease in this patient?
   Answer: Rosuvastatin 20 mg daily This patient is at high risk for a primary ASCVD event, with a calculated 10-year risk of 30% (>20%). Current guidelines strongly recommend initiating high-intensity statin therapy for such individuals. Rosuvastatin 20 mg is a high-intensity statin. Ezetimibe is not a first-line agent for primary prevention. The use of aspirin for primary prevention is a more nuanced decision involving a discussion of risks and benefits and is not the most critical initial intervention. Clopidogrel is not indicated for primary prevention.
8. In addition to smoking cessation and an exercise program, which medication is most important to initiate for secondary prevention of cardiovascular events?
   Answer: High-intensity statin therapy This patient has symptomatic peripheral artery disease (PAD), which is a form of atherosclerotic cardiovascular disease (ASCVD). Patients with clinical ASCVD are at very high risk for future cardiovascular events, including myocardial infarction and stroke. Guideline-directed medical therapy for all patients with PAD includes high-intensity statin therapy (e.g., atorvastatin 40-80 mg or rosuvastatin 20-40 mg) to lower LDL cholesterol by at least 50%, regardless of the baseline LDL level. Cilostazol is for symptom management (claudication) and does not prevent cardiovascular events.
9. Which of the following is the most appropriate lipid-lowering therapy for this patient?
   Answer: Atorvastatin 10 mg daily For patients aged >50 with chronic kidney disease (CKD) not treated with dialysis, guidelines recommend treatment with a statin or a statin/ezetimibe combination. Due to the altered metabolism and increased risk of myopathy in patients with severe CKD, initiation of high-intensity statins is generally avoided. A moderate-intensity statin, such as atorvastatin 10-20 mg, is the recommended approach. Gemfibrozil should not be used with statins due to a high risk of myopathy.
10. In addition to lifestyle modifications, which of the following is the most immediate therapeutic goal?
    Answer: Lower triglycerides to reduce the risk of pancreatitis While managing all aspects of this patient's dyslipidemia is important for long-term ASCVD risk reduction, severe hypertriglyceridemia (typically defined as >500 mg/dL) poses a significant short-term risk of acute pancreatitis. Therefore, the most immediate goal is to lower triglyceride levels. This is typically achieved with fibrate therapy (e.g., fenofibrate), high-dose omega-3 fatty acids, and aggressive lifestyle changes, including strict dietary fat restriction and glycemic control. Once triglycerides are lowered, attention can be more focused on LDL cholesterol.
11. Which of the following medical therapies is most critical to initiate immediately for secondary prevention of stroke?
    Answer: High-intensity statin and aspirin This patient has experienced a transient ischemic attack (TIA), which is an atherosclerotic cardiovascular disease event. Immediate initiation of antiplatelet therapy (aspirin) and high-intensity statin therapy is crucial for secondary stroke prevention, regardless of the patient's baseline LDL cholesterol. Dual antiplatelet therapy with aspirin and clopidogrel (not ticagrelor) may be considered for a short duration (21-90 days) for minor stroke or high-risk TIA, but aspirin and a high-intensity statin are the core initial components.
12. Which of the following is the most appropriate initial weekly exercise goal for cardiovascular risk reduction?
    Answer: 150 minutes of moderate-intensity aerobic activity The American Heart Association and US guidelines recommend that adults should engage in at least 150 minutes per week of moderate-intensity aerobic physical activity or 75 minutes per week of vigorous-intensity aerobic activity (or an equivalent combination) for substantial health benefits. For a sedentary individual, starting with a goal of 150 minutes of moderate-intensity activity (e.g., 30 minutes, 5 days a week of brisk walking) is a standard and achievable initial recommendation.
13. In addition to initiating pharmacotherapy, which of the following single lifestyle modifications will likely have the greatest impact on lowering her blood pressure?
    Answer: Weight loss of 10 kg (22 lbs) While all listed options are beneficial for blood pressure control, weight loss has the most significant effect. On average, blood pressure is reduced by approximately 1 mmHg for every 1 kg of weight loss. A 10 kg weight loss can lead to a 5-10 mmHg reduction in systolic blood pressure. The DASH diet can lower SBP by about 11 mmHg, but achieving this requires significant dietary changes. Sodium restriction and exercise have slightly smaller, though still important, effects. Given her obesity, weight loss is the most impactful single intervention.
14. What is the most appropriate recommendation regarding the duration of her antiplatelet therapy?
    Answer: Continue aspirin indefinitely and ticagrelor for at least 12 months After an acute coronary syndrome (ACS) treated with a drug-eluting stent, dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor (like ticagrelor or clopidogrel) is indicated to prevent stent thrombosis and recurrent ischemic events. The standard duration for DAPT is at least 12 months. After this period, aspirin is typically continued indefinitely for secondary prevention. The P2Y12 inhibitor may be stopped or continued depending on the patient's ischemic versus bleeding risk.
15. Which of the following dietary patterns is most strongly recommended for lowering blood pressure and reducing cardiovascular risk?
    Answer: DASH diet The Dietary Approaches to Stop Hypertension (DASH) diet is a well-established dietary pattern proven to lower blood pressure and reduce cardiovascular risk. It emphasizes fruits, vegetables, whole grains, and low-fat dairy products while limiting intake of sodium, saturated fat, cholesterol, and red meat. It has been shown to lower systolic blood pressure by 8-14 mmHg, an effect comparable to some first-line antihypertensive medications. The other diets listed do not have the same level of evidence for blood pressure reduction.
16. Based on this new information, what is the most appropriate recommendation?
    Answer: Withhold statin therapy and reassess in 5 years In intermediate-risk patients (ASCVD risk 7.5% to <20%) who are uncertain about starting a statin, a CAC score can be a useful tool for shared decision-making. A CAC score of 0 indicates a very low burden of coronary atherosclerosis and a lower-than-expected short-term cardiovascular risk. In such cases, it is reasonable to withhold statin therapy and continue to focus on lifestyle modifications, with a plan to reassess risk in 5 to 10 years. This approach avoids unnecessary medication in a lower-risk individual.
17. Which of the following represents the most effective strategy for smoking cessation in this patient?
    Answer: Prescribe varenicline combined with behavioral counseling The most effective smoking cessation strategies involve a combination of pharmacotherapy and behavioral support. Varenicline is one of the most effective single pharmacologic agents. Combining it with behavioral counseling significantly increases quit rates compared to either modality alone. For a patient who has failed monotherapy with nicotine replacement, escalating to a more effective agent like varenicline or using combination therapy (e.g., patch plus short-acting nicotine replacement or varenicline/bupropion plus counseling) is the recommended approach.
18. Which of the following is the most appropriate recommendation regarding aspirin for primary prevention in this patient?
    Answer: Engage in shared decision-making, discussing the modest benefit versus increased bleeding risk Current guidelines for primary prevention of ASCVD recommend a selective approach to aspirin therapy. For adults aged 40-70 years at higher ASCVD risk but not at increased bleeding risk, low-dose aspirin might be considered. However, the net benefit is often small. Therefore, the best approach is shared decision-making, where the physician and patient discuss the potential for a small reduction in ischemic events versus the definite increase in the risk of gastrointestinal and other bleeding.
19. Which of the following is the most appropriate initial therapy for this patient's dyslipidemia?
    Answer: Atorvastatin 40 mg This patient has multiple risk factors including type 2 diabetes and hypertension, and her calculated 10-year ASCVD risk is >20%, placing her in the high-risk category for a primary prevention. According to current guidelines, patients at high risk should be started on high-intensity statin therapy. High-intensity statins include atorvastatin 40-80 mg or rosuvastatin 20-40 mg. Therefore, initiating atorvastatin 40 mg is the most appropriate choice. Rosuvastatin 10 mg is a moderate-intensity statin.
20. What is the most appropriate approach regarding statin therapy for primary prevention in this patient?
    Answer: Discuss the potential benefits and risks of initiating a moderate-intensity statin The decision to initiate statin therapy for primary prevention in adults older than 75 years is complex due to the limited data from randomized controlled trials in this age group. The potential for benefit must be weighed against the increased risk of adverse effects, polypharmacy, and drug-drug interactions. Current guidelines recommend a clinician-patient discussion about the potential benefits (reducing MI/stroke risk) and harms (myalgia, cognitive effects) before initiating therapy. If a decision is made to start, a moderate-intensity statin is often preferred.

Start this quiz